This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: N25.1 | Special Copayment Reduction: V141 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood low — congenital X-linked NDI (AVPR2 variants) presents with hypernatremic dehydration within days to weeks after birth, and most cases are diagnosed in the neonatal period or infancy. Mild urine-concentrating abnormalities may first be identified in adulthood in female carriers (heterozygotes), but first presentation of NDI with the full phenotype in adulthood is rare. Mild phenotypes in some AR AQP2 variants may be diagnosed after childhood. |
| 1. History | Waring's description of nephrogenic diabetes insipidus in 1945 → AVPR2 variants of the X-linked form identified in 1992 → AR form due to AQP2 (aquaporin 2) identified in 1994 |
| 2. Causes | X-linked AVPR2 (vasopressin V2 receptor) variants; AR or AD AQP2 (aquaporin 2) variants; loss of vasopressin responsiveness in the collecting duct → inability to concentrate urine |
| 3. Genetics | AVPR2: X-linked recessive (Xq28), expressed in males; AQP2: AR or AD (12q13.12); AVPR2 variants account for about 90% of NDI |
| 4. General epidemiology | Among all NDI, the X-linked form occurs in about 1 in 25,000 male births; the AR AQP2 form is very rare; markedly more common in boys (X-linked) |
| 5. Pathophysiology | Vasopressin (ADH) → AVPR2 → cAMP → PKA → blocked AQP2 phosphorylation and membrane translocation → inability to reabsorb water in the collecting duct → large volumes of dilute urine → hypernatremia and dehydration |
| 6. Symptoms | Fever, vomiting, irritability, polydipsia, polyuria, and growth retardation within the first weeks of life; recurrent hypernatremic dehydration; fixed low urine specific gravity and osmolality |
| 7. Signs | Urine osmolality < 200 mOsm/kg (no response even after vasopressin administration); elevated serum sodium; urine specific gravity 1.001–1.005; no response to high-dose vasopressin |
| 8. Screening | Boys with a family history: neonatal urine osmolality and specific gravity testing; genetic analysis (AVPR2, AQP2); watch for clinical symptoms of dehydration |
| 9. Diagnosis | Water deprivation test + vasopressin (DDAVP) response test; gene panel (AVPR2, AQP2); differentiation from central DI |
| 10. Treatment | Adequate fluid intake (free water); low-salt, low-protein diet; thiazide diuretic + amiloride; indomethacin (children); DDAVP is ineffective in the nephrogenic form |
| 11. Prognosis | Normal growth and development possible with early diagnosis and treatment; recurrent dehydration and hypernatremia carry a risk of neurodevelopmental damage; hydroureteronephrosis may develop; persistent polyuria and polydipsia |
| 12. Prevention | Fetal sex determination for carrier mothers in X-linked families; genetic counseling; plan for early fluid supply; minimize heat exposure from food and environment |
| 13. References | 10 key references (with PMID or DOI) |
Nephrogenic diabetes insipidus (NDI) is a disease in which the kidneys do not respond to antidiuretic hormone (vasopressin, ADH), so urine cannot be concentrated and large volumes of dilute urine are excreted. Unlike central diabetes insipidus (failure of pituitary ADH production), the key pathophysiological feature of nephrogenic diabetes insipidus is that the renal tubules do not respond even though serum ADH levels are normal or elevated.
The first systematic description of nephrogenic diabetes insipidus was in 1945, when Waring, Tappan, and Ħoltermann in the United States reported male patients with familial diabetes insipidus and proposed an X-linked mode of inheritance. In 1947 Waring et al. first used the term 'nephrogenic', clearly distinguishing it from central diabetes insipidus. Initially, renal insensitivity to vasopressin was presumed to be the cause, but the molecular mechanism at the receptor level was elucidated decades later.
In 1992, van den Ouweland et al. and Birnbaumer et al. independently cloned the AVPR2 gene encoding the vasopressin V2 receptor on the long arm of the X chromosome (Xq28) and first reported pathogenic variants of this gene in patients with X-linked nephrogenic diabetes insipidus. This was a landmark discovery that established the molecular genetic basis of nephrogenic diabetes insipidus. In 1994, van Lieburg et al. and Deen et al. reported that variants in the AQP2 gene, encoding the aquaporin 2 (AQP2) water channel protein, cause autosomal recessive nephrogenic diabetes insipidus.
Subsequent functional studies of AVPR2 and AQP2 elucidated in detail the vasopressin signaling pathway in the collecting duct (AVPR2 → Gs → adenylyl cyclase → cAMP → PKA → AQP2 phosphorylation → AQP2 membrane translocation), which led to the discovery of new therapeutic targets. To date, more than 250 pathogenic variants have been reported in the AVPR2 gene and more than 60 in the AQP2 gene. Cases of congenital nephrogenic diabetes insipidus have also been reported in Korea, and it is registered and managed under Special Copayment Reduction code V141.
Congenital nephrogenic diabetes insipidus is caused by pathogenic variants in genes encoding key proteins of the signaling pathway through which vasopressin induces urine concentration in the collecting duct.
AVPR2 (vasopressin V2 receptor) variants: AVPR2 is located on the long arm of the X chromosome (Xq28) and is a Gs-coupled G protein-coupled receptor expressed on the basolateral membrane of collecting duct principal cells. When vasopressin (ADH) binds to AVPR2, signaling proceeds as follows: adenylyl cyclase activation → cAMP production → PKA activation → AQP2 phosphorylation → insertion of AQP2 from intracellular vesicles into the cell membrane → increased water permeability on the luminal side of the collecting duct. AVPR2 variants cause loss of function through various mechanisms, including reduced cell-membrane expression of the receptor, abnormal ligand binding, abnormal G protein coupling, and abnormal signal transduction. With X-linked recessive inheritance, the full phenotype appears in hemizygous males. AVPR2 variants account for about 90% of all congenital NDI.
AQP2 (aquaporin 2) variants: AQP2 is located on the long arm of chromosome 12 (12q13.12) and is a water channel protein located in the apical membrane and intracellular vesicles of collecting duct principal cells. AQP2 variants are expressed as autosomal recessive (loss of function of both AQP2 alleles) or rarely autosomal dominant (dominant-negative variant of one allele). AR AQP2 variants account for about 10% of all congenital NDI, and AD AQP2 variants are very rare. In the AR form, both males and females can be affected.
The mode of inheritance of congenital nephrogenic diabetes insipidus is distinguished as X-linked recessive or autosomal recessive/dominant depending on the causative gene.
X-linked recessive NDI (AVPR2 variants): pathogenic variants of AVPR2 (Xq28) are inherited in an X-linked recessive manner. Full NDI appears in males (hemizygous variant carriers), and female heterozygous carriers are mostly asymptomatic, but a mild decrease in urine-concentrating ability may be observed (some female carriers may develop symptoms depending on skewed X inactivation). More than 250 types of AVPR2 variants have been reported, including missense (most common), nonsense, deletion/insertion, and splicing variants. According to variant type and mechanism of receptor loss of function, they are classified into 4 classes: Class I (absent/low mRNA), Class II (retention in the endoplasmic reticulum → ligand binding possible but no membrane expression), Class III (expressed on the cell membrane but impaired ligand binding), Class IV (normal expression and binding but abnormal signal transduction).
Autosomal recessive NDI (AR AQP2 variants): expressed with variants in both alleles of AQP2 (12q13.12); when each parent is a heterozygous carrier (asymptomatic), 25% of children are affected. Risk is increased with consanguineous marriage. More than 70 variants have been reported, and abnormal protein folding and abnormal cell-membrane targeting are the main mechanisms.
Autosomal dominant NDI (AD AQP2 variants): very rare (about 10 cases); expressed through a dominant-negative effect in which AQP2 C-terminal variants interfere with cell-membrane targeting of wild-type AQP2. When one parent is affected, it is transmitted to 50% of children. Onset in adulthood is also possible.
Genetic testing: AVPR2 variant analysis (confirmation of hemizygous males and heterozygous female carriers), AQP2 variant analysis (in AR families). Once the familial variant is identified, prenatal/preimplantation genetic diagnosis is possible. In X-linked families, prenatal AVPR2 analysis is considered in male pregnancies after fetal sex determination.
Among congenital nephrogenic diabetes insipidus, the X-linked form (AVPR2 variants) has an incidence of about 1 in 25,000 male births and is the most common hereditary form of nephrogenic diabetes insipidus overall. The form caused by AR AQP2 variants is much rarer, with tens to hundreds of families reported worldwide. AD AQP2 variants are extremely rare, with only about 10 families described worldwide.
Sex distribution: the X-linked form appears in almost all males, and symptoms appear very rarely in females (skewed X inactivation). The AR AQP2 form appears equally in males and females. Ethnic specificity: X-linked NDI occurs in all ethnicities. Specific founder variants have been reported in some regions, but diverse variants occur sporadically worldwide. Epidemiology in Korea: based on Health Insurance Review & Assessment Service (HIRA) data, the number of registered patients with NDI (N25.1) is estimated at a few hundred or fewer, and it is registered and managed under Special Copayment Reduction code V141. Case reports of X-linked NDI continue to be published in Korean pediatric nephrology and endocrinology. Among all diabetes insipidus, the nephrogenic form accounts for about 10–15% and the central form for about 85–90%.
The key mechanism of urine concentration in the kidney is vasopressin-responsive water reabsorption in the collecting duct. A genetic defect at any step of this pathway results in nephrogenic diabetes insipidus.
Normal vasopressin signaling pathway: ① Increased plasma osmolality or decreased blood volume stimulates vasopressin (AVP) secretion from the hypothalamus. ② Circulating vasopressin binds to AVPR2 on the basolateral membrane of renal collecting duct principal cells. ③ AVPR2 activates the Gs protein and generates cAMP via adenylyl cyclase. ④ cAMP activates PKA (protein kinase A), which phosphorylates C-terminal serines of AQP2 (Ser256, Ser261, Ser264, Ser269). ⑤ Phosphorylated AQP2 moves from intracellular vesicles to the luminal cell membrane (exocytosis). ⑥ AQP2 inserted into the cell membrane forms water channels, allowing water reabsorption from the collecting duct lumen into the interstitium.
Pathophysiology of NDI: with AVPR2 variants, loss of receptor function prevents cAMP production, making AQP2 phosphorylation and membrane translocation impossible. With AQP2 variants, there is loss of function of the water channel protein itself or failure of cell-membrane expression. In both cases, water permeability on the luminal side of collecting duct principal cells decreases, making urine concentration impossible. As a result, 3–20 liters a day (in adults), or in infants a very large amount relative to body weight, of dilute urine (osmolality < 200 mOsm/kg, specific gravity 1.001–1.005) is produced. Polydipsia develops to compensate for polyuria, and if fluid intake is insufficient, hypernatremia, dehydration, and high fever occur. This can lead to fatal complications, especially in newborns and infants who cannot regulate their own fluid intake.
Symptoms of congenital nephrogenic diabetes insipidus begin to appear within days to weeks after birth. In newborns who are not fed sufficiently or are exposed to a hot environment, emergencies due to hypernatremic dehydration can occur.
Neonatal symptoms: within days of birth, unusually large amounts of dilute urine (frequently wet diapers), expressions of excessive thirst during feeding (irritability, crying), fever (dehydration fever), vomiting, and poor weight gain appear. In boys with X-linked NDI without a family history, it may initially be mistaken for infection or metabolic disease. Hypernatremia (serum Na+ > 150 mEq/L) is characteristic, and in severe cases seizures, altered consciousness, and brain damage can occur.
Childhood symptoms: polydipsia and polyuria persist and interfere with daily life (nocturnal enuresis during sleep, frequent use of school restrooms). Growth retardation may appear, with contributions from recurrent episodes of hypernatremia, caloric deficiency (reduced food intake because the stomach is filled with water), chronic kidney disease, and others. Developmental delay and intellectual disability can occur as a result of brain damage from recurrent hypernatremic dehydration.
Urinary tract dilation: chronic polyuria increases bladder volume, and dilation of the ureters and renal pelvis (hydroureteronephrosis) can develop. This is functional urinary tract dilation without lower urinary tract obstruction and is found on renal ultrasound.
Systemic symptoms: sleep disturbance due to polydipsia and polyuria (nocturnal polyuria) and social limitations due to frequent restroom use are an ongoing burden on daily life. If not treated appropriately, malnutrition, developmental delay, and repeated hospitalizations become problems.
Physical examination: signs of dehydration (decreased skin turgor, dry mucosa, sunken anterior fontanelle, absence of tears). Neurological changes in hypernatremic dehydration (irritability, high-pitched cry, hyperreflexia, altered consciousness). Excessive wetting of diapers with urine. Growth retardation (decline in height and weight percentiles). On abdominal examination, bladder enlargement or kidney enlargement (with hydronephrosis) may be found.
Laboratory findings: elevated serum sodium (> 145 mEq/L, > 160–170 mEq/L in severe cases). Elevated serum osmolality (> 295 mOsm/kg). Abnormally low urine osmolality (< 200 mOsm/kg, < 100 mOsm/kg in severe cases). Urine specific gravity 1.001–1.005. Serum BUN and creatinine: may be elevated with severe dehydration (systemic renal failure). Urine proteinuria: absent or minimal.
Vasopressin (DDAVP) stimulation test: change in urine osmolality is measured after intranasal or subcutaneous administration of 1-desamino-8-D-arginine vasopressin (dDAVP, desmopressin). Normal: urine osmolality rises to > 600 mOsm/kg or more after DDAVP. Central DI: urine osmolality rises > 50% after DDAVP. Nephrogenic NDI: minimal change in urine osmolality after DDAVP (< 10% or absolute rise < 150 mOsm/kg). This test is the key tool for differentiating central from nephrogenic diabetes insipidus.
Renal ultrasound: bladder enlargement, ureteral dilation, and renal pelvic dilation (functional hydroureteronephrosis) may be seen. Kidney size is usually normal and echogenicity is normal.
Universal newborn screening for congenital nephrogenic diabetes insipidus is not performed. Screening based on family history and clinical symptoms is key.
Screening within high-risk families: boys born into X-linked NDI families undergo urine osmolality and specific gravity testing and serum sodium and osmolality measurement from immediately after birth. When the familial AVPR2 variant has been identified, confirmatory molecular genetic testing is performed immediately at birth. In AR AQP2 NDI families, the same approach applies to both male and female newborns. Because affected boys may develop symptoms within the first few days of life, when a family history is confirmed, a fluid supply plan is established in advance and a pediatric nephrology team is involved from immediately after birth.
Screening based on clinical suspicion: even without a family history, in newborns showing recurrent fever, dehydration, and hypernatremia, excessive production of dilute urine, excessive thirst (crying, irritability), or growth retardation within days to weeks after birth, NDI is immediately included in the differential diagnosis and urine osmolality, urine specific gravity, and serum sodium are tested. Excessive wetting of diapers may be the first clue, and early recognition in the newborn nursery of the delivery hospital is important.
Prenatal screening: in pregnancies of mothers who are AVPR2 variant carriers (heterozygous), after sex determination (confirmation of a male fetus), fetal AVPR2 gene analysis is performed by chorionic villus sampling or amniocentesis. Preimplantation genetic testing (PGT) is also offered as an option. When diagnosed prenatally, a fluid supply plan and pediatric nephrology team consultation are prepared during preparation for delivery.
Confirmation of nephrogenic diabetes insipidus rests on two pillars: demonstration of unresponsiveness to vasopressin (functional testing) and genetic analysis (molecular confirmation).
Fluid Deprivation Test: in newborns and infants, the fluid deprivation test must be performed cautiously because of the risk of dehydration. If serum sodium is > 145 mEq/L before testing or the patient is already dehydrated, only the DDAVP response test is performed without fluid deprivation. During the fluid deprivation test, when serum osmolality reaches 295 mOsm/kg or more, the test is stopped and the vasopressin test is performed. DDAVP response test: urine osmolality is measured within 2–4 hours after intranasal (infants: 1–2 mcg) or subcutaneous (0.1–1 mcg/kg) dDAVP. Nephrogenic NDI: minimal change in urine osmolality (< 10% or < 150 mOsm/kg rise). Central DI: urine osmolality rises > 50%.
Genetic analysis: AVPR2 variant analysis: in boys (X-linked hemizygous), direct AVPR2 gene analysis (Sanger or NGS) concurrently with clinical diagnosis. Also used to identify female carriers. AQP2 variant analysis: performed when an AR or AD form is suspected, particularly in girls or in NDI with a negative family history. NGS-based kidney gene panels should include both AVPR2 and AQP2.
Plasma vasopressin (AVP) measurement: elevated plasma AVP (normal or abnormally high) under fluid deprivation suggests nephrogenic NDI (in central DI, AVP is low or absent). The test is technically difficult and results must be interpreted with caution.
Differential diagnosis: exclude central diabetes insipidus (responsive to DDAVP, low plasma AVP), psychogenic polydipsia (diluted serum osmolality, normal ADH levels), renal glycosuria, renal tubular acidosis, Bartter syndrome, and bladder dysfunction.
The goals of treatment of nephrogenic diabetes insipidus are to prevent dehydration and hypernatremia through adequate fluid supply and to reduce urine volume to improve convenience of daily life and growth and development. DDAVP (desmopressin) is ineffective in nephrogenic diabetes insipidus and is not used.
Fluid supply: the most important treatment is adequate free water supply. In newborns and infants, additional water (free water) beyond breast milk or formula is needed, and fluid is supplied to match daily urine output. In older children who can regulate their own polydipsia, drinking according to thirst is allowed. When oral intake is difficult because of vomiting or diarrhea, intravenous or nasogastric fluid supply is needed. When correcting hypernatremia, serum sodium must be lowered slowly (a decrease of 12 mEq/L or less over > 24 hours). Rapid correction carries a risk of cerebral edema.
Low-salt, low-protein diet: reduces solute load to decrease obligatory urine output. A low-salt (sodium-restricted) and low-protein diet minimizes the burden of renal solute excretion. In infants, adjustment of formula composition or low-salt, low-protein weaning food is needed.
Thiazide diuretics: hydrochlorothiazide (HCTZ) is the standard drug treatment for NDI. It increases sodium and water reabsorption in the proximal tubule, reducing distal water delivery and decreasing urine volume by about 25–50%. Pediatric dose: HCTZ 1–2 mg/kg/day in 2 divided doses. Hypokalemia monitoring is required.
Combination with amiloride: combining amiloride (an ENaC inhibitor) with HCTZ prevents thiazide-induced hypokalemia and provides an additional reduction in urine volume through inhibition of sodium reabsorption in the collecting duct. Pediatric dose: 0.1–0.3 mg/kg/day.
Indomethacin: reduces glomerular filtration rate and urine volume through prostaglandin inhibition. Combined with a thiazide, it has a stronger effect in reducing urine volume. It can be used in children, but gastrointestinal adverse effects (gastric ulcer) and nephrotoxicity must be watched for.
Investigational treatments: pharmacological chaperone therapies that rescue misfolded AVPR2 (class II variants) from the ER are being studied. SR49059 (a V1a receptor antagonist), vaptans (nonpeptide V2 receptor antagonists), and others are in clinical trials as strategies to improve receptor traffficking in AVPR2 class II variants.
The prognosis of congenital nephrogenic diabetes insipidus depends greatly on early diagnosis and appropriate treatment. In appropriately managed patients, near-normal growth, development, and life expectancy are possible.
Neurodevelopmental prognosis: recurrent episodes of hypernatremic dehydration increase the risk of brain cell damage, developmental delay, and intellectual disability. Hypernatremia within the first few years of life is the most dangerous, and early diagnosis and fluid supply can markedly reduce this risk. Mild to moderate neurodevelopmental delay has been reported in patients who experienced recurrent dehydration because of delayed diagnosis.
Growth prognosis: normal growth is possible in patients supplied with sufficient calories and fluid. Gastric distension and reduced food intake due to polydipsia may affect growth, so optimization of dietary composition is needed. The effect of long-term use of treatment drugs (indomethacin) on growth is assessed regularly.
Renal function prognosis: in appropriately treated patients, renal function is usually maintained as normal. However, lower urinary tract dysfunction due to chronic polyuria (bladder enlargement, functional hydronephrosis) can occur, which is managed with bladder training and drug treatment. Progression to chronic kidney disease has been reported in some, but it is rare when well treated.
Quality of life: sleep disturbance due to polydipsia, polyuria, and nocturnal polyuria, and limitations in school life and social activities are chronic factors reducing quality of life. Psychosocial support for patients and families and education in practical coping strategies are important. Even in adulthood, persistent polydipsia and polyuria affect career choice, travel, and social activities.
Female carriers: female carriers (heterozygous) of X-linked NDI are mostly asymptomatic, but mild urine-concentrating abnormalities may appear in some due to skewed X inactivation. Because there is a risk of worsening diabetes insipidus during pregnancy and delivery, caution is needed in obstetric management.
Prevention of nephrogenic diabetes insipidus consists of three levels: preventing the birth of affected boys through genetic counseling and prenatal/preimplantation genetic testing (primary prevention), preventing complications (hypernatremia, developmental delay) through early diagnosis and fluid supply (secondary prevention), and monitoring for urinary tract complications and drug adverse effects (tertiary prevention).
Primary prevention — genetic counseling and prenatal diagnosis: in X-linked NDI families where the mother is an AVPR2 variant carrier (heterozygous), after fetal sex determination during pregnancy, AVPR2 gene analysis is performed by chorionic villus sampling or amniocentesis in male pregnancies. Implantation of affected male embryos can be prevented through preimplantation genetic testing (PGT). In AR AQP2 NDI families, when the parents are confirmed carriers (heterozygous), the 25% risk of an affected child in the next pregnancy is explained and prenatal/preimplantation genetic diagnosis is offered. Genetic counseling is nondirective and supports the parents' decisions.
Secondary prevention — early diagnosis and fluid supply: in newborns with a confirmed family history, urine osmolality and serum sodium are monitored from immediately after birth, and as soon as abnormal findings are detected, a fluid supply plan is established with the involvement of a pediatric nephrology team. An immediate fluid supply protocol is prepared through prior consultation with the pediatric nephrology team before delivery. Exposure to hot environments is minimized, and additional fluid is supplied immediately in case of fever.
Tertiary prevention — monitoring for complications: renal function, serum electrolytes (sodium, potassium), growth, renal ultrasound (assessment of urinary tract dilation), and neurodevelopment are assessed regularly. Adverse effects during drug treatment (thiazides, indomethacin) (hypokalemia, gastrointestinal symptoms, nephrotoxicity) are continuously monitored. Education about NDI is provided to schools and childcare facilities to ensure sufficient access to water.